Results of Moon and colleagues suggested that the possible crosstalk between Akt/mTOR and MAPK/ERK pathway might help NVP-EBZ235 and cisplatin combination therapy treat bladder cancer (30). This evidence concerns the gene MTOR and urinary bladder carcinoma.